Base-case results of the analysis of cost-effectiveness for the 4 treatment strategies
| Strategy . | Cost . | QALY . | ICER . | Cost saved by stop TKI . |
|---|---|---|---|---|
| US analysis in USD | ||||
| Without stop TKI | ||||
| Imatinib first | 1 114 358 | 7.26 | ||
| Physician’s choice | 1 347 721 | 7.44 | 1 281 231 | |
| Nilotinib first | 1 500 262 | 7.50 | 1 315 100 | |
| Dasatinib first | 1 429 013 | 7.57 | 1 256 379 | |
| With stop TKI at MR4.5 for 2 y | ||||
| Imatinib first | 1 022 148 | 7.34 | 92 210 | |
| Physician’s choice | 1 167 818 | 7.55 | 666 634 | 179 903 |
| Nilotinib first | 1 245 667 | 7.64 | 696 717 | 192 961 |
| Dasatinib first | 1 236 052 | 7.68 | 641 324 | 254 595 |
| With stop TKI at MR4.0 for 2 y | ||||
| Imatinib first | 998 197 | 7.36 | 116 161 | |
| Physician’s choice | 1 112 415 | 7.60 | 485 386 | 235 306 |
| Nilotinib first | 1 177 994 | 7.69 | 548 509 | 251 020 |
| Dasatinib first | 1 161 600 | 7.74 | 432 113 | 338 662 |
| Japanese analysis in JPY | ||||
| Without stop TKI | ||||
| Imatinib first | 35 079 009 | 7.26 | ||
| Physician’s choice | 47 110 318 | 7.44 | 66 055 404 | |
| Nilotinib first | 46 934 624 | 7.50 | 49 550 510 | |
| Dasatinib first | 59 436 959 | 7.57 | 79 301 617 | |
| With stop TKI at MR4.5 for 2 y | ||||
| Imatinib first | 32 526 785 | 7.34 | 2 552 224 | |
| Physician’s choice | 41 187 740 | 7.55 | 39 635 615 | 5 922 578 |
| Nilotinib first | 39 635 598 | 7.64 | 23 154 465 | 7 299 026 |
| Dasatinib first | 51 506 254 | 7.68 | 54 456 325 | 7 930 706 |
| With stop TKI at MR4.0 for 2 y | ||||
| Imatinib first | 31 888 894 | 7.36 | 3 190 115 | |
| Physician’s choice | 39 293 527 | 7.60 | 31 467 039 | 7 816 791 |
| Nilotinib first | 37 691 159 | 7.69 | 17 701 079 | 9 243 465 |
| Dasatinib first | 48 439 329 | 7.74 | 43 766 827 | 10 997 630 |
| Strategy . | Cost . | QALY . | ICER . | Cost saved by stop TKI . |
|---|---|---|---|---|
| US analysis in USD | ||||
| Without stop TKI | ||||
| Imatinib first | 1 114 358 | 7.26 | ||
| Physician’s choice | 1 347 721 | 7.44 | 1 281 231 | |
| Nilotinib first | 1 500 262 | 7.50 | 1 315 100 | |
| Dasatinib first | 1 429 013 | 7.57 | 1 256 379 | |
| With stop TKI at MR4.5 for 2 y | ||||
| Imatinib first | 1 022 148 | 7.34 | 92 210 | |
| Physician’s choice | 1 167 818 | 7.55 | 666 634 | 179 903 |
| Nilotinib first | 1 245 667 | 7.64 | 696 717 | 192 961 |
| Dasatinib first | 1 236 052 | 7.68 | 641 324 | 254 595 |
| With stop TKI at MR4.0 for 2 y | ||||
| Imatinib first | 998 197 | 7.36 | 116 161 | |
| Physician’s choice | 1 112 415 | 7.60 | 485 386 | 235 306 |
| Nilotinib first | 1 177 994 | 7.69 | 548 509 | 251 020 |
| Dasatinib first | 1 161 600 | 7.74 | 432 113 | 338 662 |
| Japanese analysis in JPY | ||||
| Without stop TKI | ||||
| Imatinib first | 35 079 009 | 7.26 | ||
| Physician’s choice | 47 110 318 | 7.44 | 66 055 404 | |
| Nilotinib first | 46 934 624 | 7.50 | 49 550 510 | |
| Dasatinib first | 59 436 959 | 7.57 | 79 301 617 | |
| With stop TKI at MR4.5 for 2 y | ||||
| Imatinib first | 32 526 785 | 7.34 | 2 552 224 | |
| Physician’s choice | 41 187 740 | 7.55 | 39 635 615 | 5 922 578 |
| Nilotinib first | 39 635 598 | 7.64 | 23 154 465 | 7 299 026 |
| Dasatinib first | 51 506 254 | 7.68 | 54 456 325 | 7 930 706 |
| With stop TKI at MR4.0 for 2 y | ||||
| Imatinib first | 31 888 894 | 7.36 | 3 190 115 | |
| Physician’s choice | 39 293 527 | 7.60 | 31 467 039 | 7 816 791 |
| Nilotinib first | 37 691 159 | 7.69 | 17 701 079 | 9 243 465 |
| Dasatinib first | 48 439 329 | 7.74 | 43 766 827 | 10 997 630 |
ICER, incremental cost-effectiveness ratio (in comparison with imatinib first); NA, not applicable.